Skip to main content
Top

19-07-2017 | Cardiovascular disorders | Review | Article

Vascular complications in diabetes: old messages, new thoughts

Journal: Diabetologia

Authors: Josephine M. Forbes, Amelia K. Fotheringham

Publisher: Springer Berlin Heidelberg

Abstract

In parallel with the growing diabetes pandemic, there is an increasing burden of micro- and macrovascular complications, occurring in the majority of patients. The identification of a number of synergistic accelerators of disease, providing therapeutic pathways, has stabilised the incidence of complications in most western nations. However, the primary instigators of diabetic complications and, thus, prevention strategies, remain elusive. This has necessitated a refocus on natural history studies, where tissue and plasma samples are sequentially taken to determine when and how disease initiates. In addition, recent Phase III trials, wherein the pleiotropic effects of compounds were arguably as beneficial as their glucose-lowering capacity in slowing the progression of complications, have identified knowledge gaps. Recently the influence of other widely recognised pathological pathways, such as mitochondrial production of reactive oxygen species, has been challenged, highlighting the need for a diverse and robust global research effort to ascertain viable therapeutic targets. Technological advances, such as -omics, high-resolution imaging and computational modelling, are providing opportunities for strengthening and re-evaluating research findings. Newer areas such as epigenetics, energetics and the increasing scrutiny of our synergistic inhabitants, the microbiota, also offer novel targets as biomarkers. Ultimately, however, this field requires concerted lobbying to support all facets of diabetes research.
Literature
1.
Forbes JM, Cooper ME (2013) Mechanisms of diabetic complications. Physiol Rev 93:137–188CrossRefPubMed
2.
Geiss LS, Wang J, Cheng YJ et al (2014) Prevalence and incidence trends for diagnosed diabetes among adults aged 20 to 79 years, United States, 1980-2012. JAMA 312:1218–1226CrossRefPubMed
3.
Schultz CJ, Konopelska-Bahu T, Dalton RN et al (1999) Microalbuminuria prevalence varies with age, sex, and puberty in children with type 1 diabetes followed from diagnosis in a longitudinal study. Oxford Regional Prospective Study Group. Diabetes Care 22:495–502CrossRefPubMed
4.
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
5.
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
6.
Ceriello A (2012) The emerging challenge in diabetes: the “metabolic memory”. Vasc Pharmacol 57:133–138CrossRef
7.
Chilelli NC, Burlina S, Lapolla A (2013) AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a “glycoxidation-centric” point of view. Nutr Metab Cardiovasc Dis 23:913–919CrossRefPubMed
8.
Gerrits EG, Lutgers HL, Kleefstra N et al (2008) Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 31:517–521CrossRefPubMed
9.
Group AtCCRiDS (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008:2545–2559
10.
Group AC (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008:2560–2572
11.
Zoungas S, Chalmers J, Neal B et al (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371:1392–1406CrossRefPubMed
12.
Palmer SC, Mavridis D, Navarese E et al (2015) Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385:2047–2056CrossRefPubMed
13.
Cho YH, Craig ME, Davis EA et al (2015) Cardiac autonomic dysfunction is associated with high-risk albumin-to-creatinine ratio in young adolescents with type 1 diabetes in AdDIT (adolescent type 1 diabetes cardio-renal interventional trial). Diabetes Care 38:676–681CrossRefPubMed
14.
Maftei O, Pena AS, Sullivan T et al (2014) Early atherosclerosis relates to urinary albumin excretion and cardiovascular risk factors in adolescents with type 1 diabetes: Adolescent type 1 Diabetes cardio-renal Intervention Trial (AdDIT). Diabetes Care 37:3069–3075CrossRefPubMed
15.
Marcovecchio ML, Woodside J, Jones T et al (2014) Adolescent type 1 diabetes cardio-renal intervention trial (AdDIT): urinary screening and baseline biochemical and cardiovascular assessments. Diabetes Care 37:805–813CrossRefPubMed
16.
Mauer M, Zinman B, Gardiner R, et al. (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361
17.
Bergenstal RM (2015) Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care 38:1615–1621CrossRefPubMed
18.
Ceriello A, Kilpatrick ES (2013) Glycemic variability: both sides of the story. Diabetes Care 36:S272–S275CrossRefPubMedPubMedCentral
19.
Correia LC, Latado A, Porzsolt F (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:1798PubMed
20.
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134:752–772CrossRefPubMed
21.
McCreight LJ, Bailey CJ, Pearson ER (2016) Metformin and the gastrointestinal tract. Diabetologia 59:426–435CrossRefPubMedPubMedCentral
22.
Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615–1625CrossRefPubMed
23.
Wang Z, Ying Z, Bosy-Westphal A et al (2010) Specific metabolic rates of major organs and tissues across adulthood: evaluation by mechanistic model of resting energy expenditure. Am J Clin Nutr 92:1369–1377CrossRefPubMedPubMedCentral
24.
Coughlan MT, Nguyen TV, Penfold SA et al (2016) Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. Clin Sci 130:711–720CrossRefPubMed
25.
Hallan S, Sharma K (2016) The role of mitochondria in diabetic kidney disease. Curr Diab Rep 16:61CrossRefPubMed
26.
Dugan LL, You YH, Ali SS et al (2013) AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J Clin Invest 123:4888–4899CrossRefPubMedPubMedCentral
27.
Persson MF, Franzen S, Catrina SB et al (2012) Coenzyme Q10 prevents GDP-sensitive mitochondrial uncoupling, glomerular hyperfiltration and proteinuria in kidneys from db/db mice as a model of type 2 diabetes. Diabetologia 55:1535–1543CrossRefPubMed
28.
Sourris KC, Harcourt BE, Tang PH et al (2012) Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 52:716–723CrossRefPubMed
29.
Chacko BK, Reily C, Srivastava A et al (2010) Prevention of diabetic nephropathy in Ins2+/˗AkitaJ mice by the mitochondria-targeted therapy MitoQ. Biochem J 432:9–19CrossRefPubMedPubMedCentral
30.
Hou Y, Li S, Wu M et al (2016) Mitochondria-targeted peptide SS-31 attenuates renal injury via an antioxidant effect in diabetic nephropathy. Am J Physiol Ren Physiol 310:F547–F559CrossRef
31.
Szeto HH, Liu S, Soong Y, Alam N, Prusky GT, Seshan SV (2016) Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int 90:997–1011CrossRefPubMed
32.
Sas KM, Kayampilly P, Byun J et al (2016) Tissue-specific metabolic reprogramming drives nutrient flux in diabetic complications. JCI Insight 1:e86976CrossRefPubMedPubMedCentral
33.
Stadler K, Goldberg IJ, Susztak K (2015) The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diab Rep 15:40CrossRefPubMedPubMedCentral
34.
Coughlan MT, Sharma K (2016) Challenging the dogma of mitochondrial reactive oxygen species overproduction in diabetic kidney disease. Kidney Int 90:272–279CrossRefPubMed
35.
Forbes JM, Coughlan MT, Cooper ME (2008) Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 57:1446–1454CrossRefPubMed
36.
The Diabetes Control and Complications Trial Research Group (1997) Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 46: 1829–1839
37.
Langefeld CD, Beck SR, Bowden DW, Rich SS, Wagenknecht LE, Freedman BI (2004) Heritability of GFR and albuminuria in Caucasians with type 2 diabetes mellitus. Am J Kidney Dis 43:796–800CrossRefPubMed
38.
Hietala K, Forsblom C, Summanen P, Groop P-H, on behalf of the FinnDiane Study Group (2008) Heritability of proliferative diabetic retinopathy. Diabetes 57:2176–2180CrossRefPubMedPubMedCentral
39.
Ma RCW (2016) Genetics of cardiovascular and renal complications in diabetes. J Diabetes Investig 7:139–154CrossRefPubMed
40.
Krolewski AS (2015) Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 38:954–962CrossRefPubMedPubMedCentral
41.
Martini S, Nair V, Patel SR et al (2013) From single nucleotide polymorphism to transcriptional mechanism: a model for FRMD3 in diabetic nephropathy. Diabetes 62:2605–2612CrossRefPubMedPubMedCentral
42.
Kato M, Natarajan R (2014) Diabetic nephropathy—emerging epigenetic mechanisms. Nat Rev Nephrol 10:517–530CrossRefPubMed
43.
Beltrami C, Angelini TG, Emanueli C (2015) Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol 89:42–50CrossRefPubMed
44.
Reddy MA, Das S, Zhuo C et al (2016) Regulation of vascular smooth muscle cell dysfunction under diabetic conditions by miR-504. Arterioscler Thromb Vasc Biol 36:864–873CrossRefPubMedPubMedCentral
45.
Sapienza C, Lee J, Powell J et al (2011) DNA methylation profiling identifies epigenetic differences between diabetes patients with ESRD and diabetes patients without nephropathy. Epigenetics 6:20–28CrossRefPubMed
46.
Bell CG, Teschendorff AE, Rakyan VK, Maxwell AP, Beck S, Savage DA (2010) Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Med Genet 3:1
47.
Brennan EP, Ehrich M, OʼDonovan H et al (2010) DNA methylation profiling in cell models of diabetic nephropathy. Epigenetics 5:396–401CrossRefPubMed
48.
Ko Y-A, Mohtat D, Suzuki M et al (2013) Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol 14:R108CrossRefPubMedPubMedCentral
49.
Estruch R, Ros E, Salas-Salvadó J et al (2013) Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368:1279–1290CrossRefPubMed
50.
Griffin JL, Wang X, Stanley E (2015) Does our gut microbiome predict cardiovascular risk? A review of the evidence from metabolomics. Circ Cardiovasc Genet 8:187–191CrossRefPubMedPubMedCentral
51.
Turnbaugh PJ, Hamady M, Yatsunenko T et al (2009) A core gut microbiome in obese and lean twins. Nature 457:480–484CrossRefPubMed
52.
Davari S, Talaei SA, Alaei H, Salami M (2013) Probiotics treatment improves diabetes-induced impairment of synaptic activity and cognitive function: behavioral and electrophysiological proofs for microbiome–gut–brain axis. Neuroscience 240:287–296CrossRefPubMed

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »